Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge,Charlie T. Garnett,Benedetto Farsaci,Claudia Palena,Kwong-Yok Tsang,Soldano Ferrone,Sofia R. Gameiro +6 more
Reads0
Chats0
TLDR
An operational definition of “immunogenic modulation,” where exposure of tumor cells to nonlethal/sublethal doses of chemotherapy alters tumor phenotype to render the tumor more sensitive to CTL killing is provided.Abstract:
Certain chemotherapeutic regimens trigger cancer cell death while inducing dendritic cell maturation and subsequent immune responses. However, chemotherapy-induced immunogenic cell death (ICD) has thus far been restricted to select agents. In contrast, several chemotherapeutic drugs modulate antitumor immune responses, despite not inducing classic ICD. In addition, in many cases tumor cells do not die after treatment. Here, using docetaxel, one of the most widely used cancer chemotherapeutic agents, as a model, we examined phenotypic and functional consequences of tumor cells that do not die from ICD. Docetaxel treatment of tumor cells did not induce ATP or high-mobility group box 1 (HMGB1) secretion, or cell death. However, calreticulin (CRT) exposure was observed in all cell lines examined after chemotherapy treatment. Killing by carcinoembryonic antigen (CEA), MUC-1, or PSA-specific CD8(+) CTLs was significantly enhanced after docetaxel treatment. This killing was associated with increases in components of antigen-processing machinery, and mediated largely by CRT membrane translocation, as determined by functional knockdown of CRT, PERK, or CRT-blocking peptide. A docetaxel-resistant cell line was selected (MDR-1(+), CD133(+)) by continuous exposure to docetaxel. These cells, while resistant to direct cytostatic effects of docetaxel, were not resistant to the chemomodulatory effects that resulted in enhancement of CTL killing. Here, we provide an operational definition of "immunogenic modulation," where exposure of tumor cells to nonlethal/sublethal doses of chemotherapy alters tumor phenotype to render the tumor more sensitive to CTL killing. These observations are distinct and complementary to ICD and highlight a mechanism whereby chemotherapy can be used in combination with immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.
TL;DR: The tremendous clinical success of checkpoint blockers illustrates the potential of reestablishing latent immunosurveillance for cancer therapy, and their in-depth comprehension will facilitate the design of novel combinatorial regimens with improved clinical efficacy.
Journal ArticleDOI
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay,Elizabeth P. Ryan,Graham Pawelec,Wamidh H. Talib,John Stagg,Eyad Elkord,Terry Lichtor,William K. Decker,Richard L. Whelan,H. M. C. Shantha Kumara,Emanuela Signori,Kanya Honoki,Alexandros G. Georgakilas,Amr Amin,William G. Helferich,Chandra S. Boosani,Gunjan Guha,Maria Rosa Ciriolo,Sophie Chen,Sulma I. Mohammed,Asfar S. Azmi,W. Nicol Keith,Alan Bilsland,Dipita Bhakta,Dorota Halicka,Hiromasa Fujii,Katia Aquilano,S. Salman Ashraf,Somaira Nowsheen,Xujuan Yang,Beom K. Choi,Byoung S. Kwon +31 more
TL;DR: The advances made toward understanding the basis of cancer immune evasion are discussed, the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection are summarized and some natural agents and phytochemicals merit further study.
Journal ArticleDOI
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens,Gary Middleton +1 more
TL;DR: This Cancer Immunology at the Crossroads article focuses on cancer vaccines and immune checkpoint blockade as a forum for reviewing preclinical and clinical data demonstrating the interplay between immunotherapy and chemotherapy.
Journal ArticleDOI
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
Sofia R. Gameiro,Momodou L. Jammeh,Max M. Wattenberg,Kwong Y. Tsang,Soldano Ferrone,James W. Hodge +5 more
TL;DR: Evidence is provided that radiation induces a continuum of immunogenic alterations in tumor biology, from immunogenic modulation to immunogenic cell death, which offers a rationale for the combined use of radiation with immunotherapy, including for patients failing RT alone.
Journal ArticleDOI
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Lucillia Bezu,Ligia C. Gomes-de-Silva,Heleen Dewitte,Karine Breckpot,Jitka Fucikova,Radek Spisek,Lorenzo Galluzzi,Oliver Kepp,Guido Kroemer +8 more
TL;DR: This work discusses current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD, and suggests that novel therapeutic regimens that trigger ICD are urgently awaited.
References
More filters
Journal ArticleDOI
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Noelia Casares,Marie O. Pequignot,Antoine Tesniere,François Ghiringhelli,Stephan Roux,Nathalie Chaput,Elise Schmitt,Ahmed Hamaï,Sandra Hervas-Stubbs,Michel Obeid,Fréderic Philippe Coutant,Didier Métivier,Evelyne Pichard,Pierre Aucouturier,Gérard Pierron,Carmen Garrido,Laurence Zitvogel,Guido Kroemer +17 more
TL;DR: It is shown that even in the absence of any adjuvant, tumor cells dying in response to anthracyclins can elicit an effective antitumor immune response that suppresses the growth of inoculated tumors or leads to the regression of established neoplasia.
Journal ArticleDOI
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
Theocharis Panaretakis,Theocharis Panaretakis,Theocharis Panaretakis,Oliver Kepp,Oliver Kepp,Oliver Kepp,Ulf Brockmeier,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Ann Charlotte Björklund,Daniel C. Chapman,Michael Durchschlag,Nicholas Joza,Nicholas Joza,Nicholas Joza,Gérard Pierron,Peter van Endert,Peter van Endert,Junying Yuan,Laurence Zitvogel,Laurence Zitvogel,Frank Madeo,David B. Williams,Guido Kroemer,Guido Kroemer,Guido Kroemer +26 more
TL;DR: Depletion of PERK, caspase‐8 or SNAREs had no effect on cell death induced by anthracyclines, yet abolished the immunogenicity of cell death, which could be restored by absorbing recombinant CRT to the cell surface.
Journal ArticleDOI
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death.
Abhishek D. Garg,Dmitri V. Krysko,Tom Verfaillie,Agnieszka Kaczmarek,Gabriela B Ferreira,Thierry Marysael,N Rubio,Malgorzata Firczuk,Malgorzata Firczuk,Chantal Mathieu,Anton J.M. Roebroek,Wim Annaert,Jakub Golab,Jakub Golab,Peter de Witte,Peter Vandenabeele,Patrizia Agostinis +16 more
TL;DR: A novel PERK‐dependent subroutine for the early and simultaneous emission of two critical DAMPs following ROS‐mediated ER stress is unraveled.
Journal ArticleDOI
Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47
Mark P. Chao,Siddhartha Jaiswal,Siddhartha Jaiswal,Rachel Weissman-Tsukamoto,Ash A. Alizadeh,Andrew J. Gentles,Jens Peter Volkmer,Kipp Weiskopf,Stephen B. Willingham,Tal Raveh,Christopher Y. Park,Ravindra Majeti,Irving L. Weissman +12 more
TL;DR: Calreticulin is identified as the “eat me’ signal on cancer cells that leads to phagocytosis when the counterbalancing “don’t eat me” signal CD47 is blocked and provides a key insight for the therapeutic development of CD47-inhibitory agents.
Journal ArticleDOI
Immune parameters affecting the efficacy of chemotherapeutic regimens
TL;DR: It is surmised that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses.
Related Papers (5)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,François Ghiringhelli,François Ghiringhelli,François Ghiringhelli,Gian Maria Fimia,Lionel Apetoh,Lionel Apetoh,Lionel Apetoh,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Maria Castedo,Maria Castedo,Maria Castedo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,Theoharis Panaretakis,Theoharis Panaretakis,Theoharis Panaretakis,Noelia Casares,Noelia Casares,Noelia Casares,Didier Métivier,Didier Métivier,Didier Métivier,Nathanael Larochette,Nathanael Larochette,Nathanael Larochette,Peter van Endert,Peter van Endert,Fabiola Ciccosanti,Mauro Piacentini,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Guido Kroemer,Guido Kroemer +41 more
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more